Showing 21-30 of 7019 results for "".
Diagnosis: “Brochure-itis”
https://practicaldermatology.com/topics/practice-management/diagnosis-brochure-itis/21604/You can make over practice websites with simple edits.Allergan Strikes $66 Billion Deal with Actavis
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-allergan-strikes-66-billion-deal-with-actavis/19021/In this edition of DermWireTV, host Ranna Jaraha discusses this week's blockbuster merger deal between Allergan and Actavis. Also featured in this edition is a new report detailing the rising costs of treating skin cancer, and high recognition for a dermatologic device manufacturer.Drug Prices Soar, Amgen Files BLA for Biosimilar to Humira
https://practicaldermatology.com/topics/practice-management/dermwiretv-drug-prices-soar-amgen-files-bla-for-biosimilar-to-humira/18672/In this edition, Amgen Submits ABP 501—first Adalimumab biosimilar; prices for dermatology drugs jump and a survey explores patient knowledge of antibiotic resistance. Also, Almirall acquires Veltin from Sitefel/GSK.Allergan Board Rejects Latest Valeant Bid; Topical Jublia Approved for Onychomycosis
https://practicaldermatology.com/series/dermwire-tv/dwtv-6-12/19122/Allergan's board rejects the latest merger proposal from Valeant and the FDA approves topical Jublia for onychomycosis. LEarn about these developments and hear from the AMA's new president in this edition of DermWireTV.Finding Meaning in a Complicated EHR Picture
https://practicaldermatology.com/topics/practice-management/finding-meaning-in-a-complicated-ehr-picture/21302/Introducing the next edition of the EHR User series, featuring perspective on individual systems and the broader HIT picture.DermwireTV — Bayer Buys Merck’s OTC Lines, Allergan Rejects Valeant Bid
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-bayer-buys-merck-rsquo-s-otc-lines-allergan-rejects-valeant-bid/19134/Bayer Purchases Merck's OTC Products and Allergan Rebuffs Valeant. This week DermWireTV explores Bayer's growth in the OTC space, including sunscreens, and reports new data on skin cancer mortality. Also in this edition: Neal Bhatia, MD reviews the Noah Worcester Society Annual Meeting.Scientifically Speaking: Botulinum Toxin Formulation and Testing
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-botulinum-toxin-formulation-and-testing/19832/Ever wonder about the differences in formulation and manufacture of botulinum neurotoxins? Curious about the trials that support approval? In this edition of Scientifically Speaking, Joel L. Cohen, MD gets the answers to these questions and more from Conor Gallagher, PhD, Head of Medical Affairs, RePart 3: New Developments in Biologics
https://practicaldermatology.com/topics/psoriasis/part-3-new-developments-in-biologics/18965/In this edition of Derm Insider, host Neal Bhatia, MD tackles the evolving systemic treatment landscape for psoriasis with guests Alice Gottlieb, MD, Harold Farber, MD, and James Ulery, MD. In Part III, they discuss new developments in biologic therapy.Bellafill Fills a Niche; Soolantra Targets Rosacea
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-bellafill-fills-a-niche-soolantra-targets-rosacea-/18995/In this edition of DermWireTV from the editors of Practical Dermatology® magazine, a look at the approval of Bellafill (Suneva) to treat acne scars and Soolantra (Ivermectin 1%, Galderma) to treat rosacea. Plus, Benzac (Galderma) is now available OTC to treat acne, and Opdivo (Bristol-Myers Squibb)Managing Hot Buttons
https://practicaldermatology.com/topics/practice-management/managing-hot-buttons/18881/Host Neal Bhatia, MD sits down with Amit Garg, MD in a special one-on-one edition of Derm Insider to talk about tips for managing stress and emotional “hot buttons” in practice. They also discuss measures clinicians can take to prevent making rash decisions and better achieve their goals.